EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus

Ja Young Jeon, Dae Jung Kim

Diabetes & Metabolism Journal · 30.09.2024 · 48 (5) · 837-846

DOI: 10.4093/dmj.2024.0317 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes & Metabolism Journal, erschienen am 30.09.2024. Verfasst von Ja Young Jeon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

People with type 2 diabetes mellitus (T2DM) are at higher risk of developing cardiovascular disease, heart failure, chronic kidney disease, and premature death than people without diabetes. Therefore, treatment of diabetes aims to reduce these complications. Sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown beneficial effects on cardiorenal and metabolic health beyond glucose control, making them a promising class of drugs for achieving the ultimate goals of diabetes treatment. However, despite their proven benefits, the use of SGLT2 inhibitors in eligible patients with T2DM remains suboptimal due to reports of adverse events. The use of SGLT2 inhibitors is particularly limited in older patients with T2DM because of the lack of treatment experience and insufficient long-term safety data. This article comprehensively reviews the risk-benefit profile of SGLT2 inhibitors in older patients with T2DM, drawing on data from prospective randomized controlled trials of cardiorenal outcomes, original studies, subgroup analyses across different age groups, and observational cohort studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHumansAgedHypoglycemic AgentsCardiovascular DiseasesRandomized Controlled Trials as TopicRisk AssessmentHeart Failure

Stichwörter der Autor:innen

AgedDiabetes mellitus, type 2Risk assessmentSodium-glucose transporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.

Zitieren

APA

Jeon, J. Y., & Kim, D. J. (2024). Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus. Diabetes & Metabolism Journal, 48(5), 837-846. https://doi.org/10.4093/dmj.2024.0317

Vancouver

Jeon JY, Kim DJ. Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus. Diabetes & Metabolism Journal. 2024;48(5):837-846. doi:10.4093/dmj.2024.0317

BibTeX
@article{Jeon2024,
  author = {Jeon, Ja Young and Kim, Dae Jung},
  title = {Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus},
  journal = {Diabetes & Metabolism Journal},
  year = {2024},
  volume = {48},
  number = {5},
  pages = {837--846},
  doi = {10.4093/dmj.2024.0317}
}
Kostenlos starten →